

PL I = Paroxysmal brain disorders & Comorbidity

1. **Bijlenga D**, Overeem S, **Fronczek R**, **Lammers GJ**. Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. *Sleep* 2022 Aug 11;45(8):zsac091. doi: 10.1093/sleep/zsac091. PMID: 35429267. (Impact Factor 5.849) PL I
2. Boele FW, den Otter PWM, **Reijneveld JC**, de Witt Hamer PC, van Thuijl HF, Lorenz LMC, Wesseling P, Lagerwaard FJ, Taphoorn MJB, Kouwenhoven MCM, Snijders TJ, Douw L, Klein M. Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades. *Neuro Oncol*. 2022 Aug 1: noac185. doi: 10.1093/neuonc/noac185. Online ahead of print. PMID: 35908832 (Impact Factor 12.300) PL I
3. Bonnett LJ, Kim L, Johnson A, **Sander JW**, Lawn N, Beghi E, Leone M, Marson AG. Risk of seizure recurrence in people with single seizures and early epilepsy – Model development and external validation. *Seizure*. 2022 Jan;94:26–32. doi: 10.1016/j.seizure.2021.11.007. Epub 2021 Nov 23. PMID: 34852983 (Impact Factor 2.980) PL I
4. Broekaart DWM, Zimmer TS, Cohen ST, Tessers R, Anink JJ, de Vries HE, Gorter JA, Prades R, **Aronica E**, van Vliet EA. The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro. *Biomedicines*. 2022 Aug 29;10(9):2117. doi: 10.3390/biomedicines10092117. PMID: 36140216 (Impact Factor 6.081) PL I
5. **Bunschoten JW**, Husein N, Devinsky O, French JA, **Sander JW**, **Thijs RD**, **Keezer MR**. Sudden Death and Cardiac Arrhythmia With Lamotrigine: A Rapid Systematic Review. *Neurology*. 2022 Apr 26;98(17):e1748–e1760. doi: 10.1212/WNL.0000000000200164 .PMID: 35260442. (Impact Factor 9.910) PL I
6. Campbell C, McCormack M, Patel S, Stapleton C, Bobbili D, Krause R, Depondt C, Sills GJ, Koeleman BP, Striano P, Zara F, **Sander JW**, Lerche H, Kunz WS, Stefansson K, Stefansson H, Doherty CP, Heinzen EL, Scheffer IE, Goldstein DB, O'Brien T, Cotter D, Berkovic SF; EpiPGX Consortium, Sisodiya SM, Delanty N, Cavalleri GL. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. *Epilepsia*. 2022 Jun;63(6):1563–1570. doi: 10.1111/epi.17228. PMID: 35298028. (Impact Factor 5.864) PL I
7. Caramanna I, Klein M, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, **Reijneveld JC**; EORTC Quality of Life Group and EORTC Brain Tumor Group. Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients. *Qual Life Res*. 2022 Nov;31(11):3253–3266. doi: 10.1007/s11136-022-03197-w. PMID: 35982202 (Impact Factor 4.147) PL I
8. Caramanna I, de Kort JM, Brandes AA, Taal W, Platten M, Idbaih A, Frenel JS, Wick W, Preetha CJ, Bendszus M, Vollmuth P, **Reijneveld JC**, Klein M. Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from

- European Organization for Research and Treatment of Cancer (EORTC) trial 26101. *Neurooncol Pract.* 2022 Mar 13;9(4):310–316. doi: 10.1093/nop/npac022. eCollection 2022 Aug. PMID: 35855458 (Impact Factor unknown) PL I
9. De Meulemeester AS, Heylen L, Siekierska A, Mills JD, Romagnolo A, Van Der Wel NN, **Aronica E**, de Witte PAM. Hyperactivation of mTORC1 in a double hit mutant zebrafish model of tuberous sclerosis complex causes increased seizure susceptibility and neurodevelopmental abnormalities. *Front Cell Dev Biol.* 2022 Sep 27;10:952832. doi: 10.3389/fcell.2022.952832. eCollection 2022. PMID: 36238691 (Impact Factor 6.684) PL I
 10. Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, **Donjacour CEHM**, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, **Lammers GJ**. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE–FAST Model Predictions. *Neurol Ther.* 2022 Dec 10. doi: 10.1007/s40120-022-00425-w. Online ahead of print. PMID: 36494591 (Impact Factor 5.814) PL I
 11. Draaisma K, Tesileanu CMS, de Heer I, Klein M, Smits M, **Reijneveld JC**, Clement PM, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Weller M, Chinot OL, Kros JM, Verschuere T, Coens C, Golfopoulos V, Gorlia T, Idbaih A, Robe PA, van den Bent MJ, French PJ. Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. *Clin Cancer Res.* 2022 Jun 1;28(11):2440–2448. doi: 10.1158/1078-0432.CCR-21-3725. PMID: 35294545 (Impact Factor 12.531) PL I
 12. Fietze I, Laharnar N, Bargiotas P, Basoglu OK, Dogas Z, Drummond M, Fanfulla F, Gislason T, Gouveris H, **Grote L**, Hein H, Jennum P, Joppa P, van Kralingen K, Kvamme JA, Lombardi C, Ludka O, Mallin W, Marrone O, McNicholas WT, Mihaicuta S, Montserrat J, Pillar G, Pataka A, Randerath W, Riha RL, Roisman G, Saaresranta T, Schiza SE, Sliwinski P, Svaza J, Steiropoulos P, Tamisier R, Testelmans D, Trakada G, Verbraecken J, Zablockis R, Penzel T. Management of obstructive sleep apnea in Europe – A 10-year follow-up. *Sleep Med.* 2022 Sep;97:64–72. doi: 10.1016/j.sleep.2022.06.001. Epub 2022 Jun 9. PMID: 35724441 (Impact Factor 3.492) PL I
 13. Ioannou P, Foster DL, **Sander JW**, Dupont S, Gil–Nagel A, Drogon O'Flaherty E, Alvarez–Baron E, Medjedovic J. The burden of epilepsy and unmet need in people with focal seizures. *Brain Behav.* 2022 Sep;12(9):e2589. doi: 10.1002/brb3.2589. Epub 2022 Aug 26. PMID: 36017757 (Impact Factor 2.708) PL I
 14. de Jong JM, Broekaart DWM, Bongaarts A, Mühlebner A, Mills JD, van Vliet EA, **Aronica E**. Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors. *Biomedicines.* 2022 Oct 3;10(10):2475. doi: 10.3390/biomedicines10102475. PMID: 36289737 (Impact Factor 6.081) PL I
 15. Kwon CS, Jacoby A, Ali A, Austin J, Birbeck GL, Braga P, Cross JH, **de Boer H**, Dua T, Fernandes PT, Fiest KM, Goldstein J, Haut S, Lorenzetti D, Mifsud J, Moshe S, Parko KL, Tripathi M, Wiebe S, Jette N. Systematic review of frequency of felt and enacted stigma in epilepsy and determining factors and attitudes toward persons living with epilepsy–Report from the International League Against Epilepsy Task Force on Stigma

- in Epilepsy. *Epilepsia*. 2022 Mar;63(3):573–597. doi: 10.1111/epi.17135. Epub 2022 Jan 5. PMID: 34985782 (Impact Factor 5.864) PL I
16. Lu L, Zhang Q, Xiao J, Zhang Y, Peng W, Han X, Chen S, Yang D, **Sander JW**, Zhou D, Xiong W. COVID–19 vaccine take–up rate and safety in adults with epilepsy: Data from a multicenter study in China. *Epilepsia*. 2022 Jan;63(1):244–251. doi: 10.1111/epi.17138. Epub 2021 Nov 21. PMID: 34806164 (Impact Factor 5.864) PL I
17. Oort Q, Zwinkels H, Koekkoek JAF, Vos MJ, **Reijneveld JC**, Taphoorn MJB, Dirven L. Is the EORTC QLQ–C30 emotional functioning scale appropriate as an initial screening measure to identify brain tumour patients who may possibly have a mood disorder? *Psychooncology*. Jun;31(6):995–1002. doi: 10.1002/pon.5889. Epub 2022 Jan 28. PMID: 35083812 (Impact Factor 3.894) PL I
18. Qin L, Zhang Y, **Sander JW**, Zhou D, Xiong W. Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation. *Mov Disord*. 2022 Mar;37(3):643–644. doi: 10.1002/mds.28889. Epub 2021 Dec 16. PMID: 34913197 No abstract available. (Impact Factor 10.338) PL I
19. Sadnicka A, **Meppelink AM**, Kalinowski A, Oakeshott P, van den Dool J. Dystonia. *BMJ*. 2022 Apr 11;377:e062659. doi: 10.1136/bmj–2020–062659. PMID: 35410890 (Impact Factor 39.890) PL I
20. **Schinkelshoek MS**, **Fronczek R**, de Boer AFJ, de Wit K, Tannemaat MR, **Lammers GJ**. Warm ears, a red flag for sleepiness? *J Sleep Res*. 2022 Aug 23:e13707. doi: 10.1111/jsr.13707. Online ahead of print. PMID: 35997128 (Impact Factor 3.981) PL I
21. Shlobin NA, **Sander JW**. Learning from the comorbidities of epilepsy. *Curr Opin Neurol*. 2022 Apr 1;35(2):175–180. doi: 10.1097/WCO.0000000000001010. PMID: 34812750 (Impact Factor 5.710) PL I
22. Singh B, Mahajan N, Singh G, **Sander JW**. Temporal trends in the epilepsy treatment gap in low– and low–middle–income countries: A meta–analysis. *J Neurol Sci*. 2022 Mar 15;434:120174. doi: 10.1016/j.jns.2022.120174. Epub 2022 Jan 31. PMID: 35144236 (Impact Factor 3.181) PL I
23. Straathof EJM, **Heineman KR**, La Bastide–van Gemert S, Hamer EG, Hadders–Algra M. Infant motor behaviour and functional and cognitive outcome at school–age: A follow–up study in very high–risk children. *Early Hum Dev*. 2022 Jul;170:105597. doi: 10.1016/j.earlhumdev.2022.105597. Epub 2022 Jun 2. PMID: 35689969 (Impact Factor 2.079) PL I
24. Touma L, Dansereau B, Chan AY, Jetté N, Kwon CS, Braun KPJ, Friedman D, Jehi L, Rolston JD, Vadera S, Wong–Kisiel LC, Englot DJ, **Keezer MR**. Neurostimulation in people with drug–resistant epilepsy: Systematic review and meta–analysis from the ILAE Surgical Therapies Commission. *Epilepsia*. 2022 Jun;63(6):1314–1329. doi: 10.1111/epi.17243. Epub 2022 Apr 18. PMID: 35352349 (Impact Factor 5.864) PL I
25. Verhoeff MC, Koutris M, de Vries R, Berendse HW, **van Dijk KD**, Lobbezoo F. Salivation in Parkinson's disease: A scoping review. *Gerodontology* 2022 Mar 4. doi: 10.1111/ger.12628. Online ahead of print. (Impact Factor 3.184) PL I
26. Verhoeff MC, Koutris M, Tambach S, Eikenboom D, de Vries R, Berendse HW, **van Dijk KD**, Lobbezoo F. Orofacial pain and dysfunction in patients with Parkinson's disease:

- A scoping review. *Eur J Pain*. 2022 Nov;26(10):2036–2059. doi: 10.1002/ejp.2031. PMID: 36063442 (Impact Factor 3.931) PL I
27. Vezzani A, Ravizza T, Bedner P, **Aronica E**, Steinhäuser C, Boison D. Astrocytes in the initiation and progression of epilepsy. *Nat Rev Neurol*. 2022 Dec;18(12):707–722. doi: 10.1038/s41582-022-00727-5. Epub 2022 Oct 24. PMID: 36280704 (Impact Factor 42.937) PL I
28. Zhang Y, Xiong W, Lu L, **Sander JW**, Zhou D. Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous MYORG Mutation. *Mov Disord*. 2022 Jan;37(1):233–235. doi: 10.1002/mds.28860. Epub 2021 Nov 16. PMID: 34783389 (Impact Factor 10.338) PL I

PL II = Refractory epilepsy

29. **Aronica E**, Binder DK, Drexel M, Ikonomidou C, Kadam SD, Sperk G, Steinhäuser C. A companion to the preclinical common data elements and case report forms for neuropathology studies in epilepsy research. A report of the TASK3 Neuropathology Working Group of the ILAE/AES Joint Translational Task Force. *Epilepsia Open*. 2022 Aug 8. doi: 10.1002/epi4.12638. Online ahead of print. PMID: 35938285 (Impact Factor unknown) PL II
30. Cho FS, Vainchtein ID, Voskobiynek Y, Morningstar AR, Aparicio F, Higashikubo B, Ciesielska A, Broekaart DWM, Anink JJ, van Vliet EA, Yu X, Khakh BS, **Aronica E**, Molofsky AV, Paz JT. Enhancing GAT-3 in thalamic astrocytes promotes resilience to brain injury in rodents. *Sci Transl Med*. 2022 Jul 6;14(652):eabj4310. doi: 10.1126/scitranslmed.abj4310. Epub 2022 Jul 6. PMID: 35857628 (Impact Factor 17.956) PL II
31. Curatolo P, **Aronica E**, Jansen A, Jansen F, Kotulska K, Lagae L, Moavero R, Jozwiak S. Corrigendum to "Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC" *J. Eur. Paediatr. Neurol.* 20 (2) (2016) 203–211. *Eur J Paediatr Neurol*. 2022 Nov;41:109 doi: 10.1016/j.ejpn.2022.09.001. PMID: 36109305 (Impact Factor 3.140) PL II
32. Fritz L, Peeters MCM, Zwinkels H, Koekkoek JAF, **Reijneveld JC**, Vos MJ, Pasman HRW, Dirven L, Taphoorn MJB. Advance care planning (ACP) in glioblastoma patients: Evaluation of a disease-specific ACP program and impact on outcomes. *Neurooncol Pract*. 2022 Jun 22;9(6):496–508. doi: 10.1093/nop/npac050. eCollection 2022 Dec. PMID: 36388414 (Impact Factor Unknown) PL II
33. Gelardi ELM, Caprioglio D, Colombo G, Del Grosso E, Mazzeletti D, Mattoteia D, Salamone S, Ferraris DM, **Aronica E**, Nato G, Buffo A, Rizzi M, Magrassi L, Minassi A, Garavaglia S. Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis. *Commun Biol*. 2022 Sep 1;5(1):895. doi: 10.1038/s42003-022-03834-7. PMID: 36050388 (Impact Factor 6.268) PL II
34. Green SF, Hare N, Kassam M, Rugg-Gunn F, Koepp MJ, **Sander JW**, Rajakulendran S. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. *Epilepsy Behav*. 2022 Oct;135:108868. doi: 10.1016/j.yebeh.2022.108868. PMID: 35985166 (Impact Factor 2.937) PL II

35. **van der Hoeven AE, Fronczek R, Schinkelshoek MS**, Roelandse FWC, Bakker JA, Overeem S, **Bijlenga D, Lammers GJ**. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. *Sleep*. 2022 May 12;45(5):zsac052. doi: 10.1093/sleep/zsac052. Epub 2022 Mar 7. PMID: 35255144 (Impact Factor 5.849) PL II
36. Hulshof HM, Kuijf HJ, Kotulska K, Curatolo P, Weschke B, Riney K, Krsek P, Feucht M, Nabbout R, Lagae L, Jansen A, Otte WM, Lequin MH, Sijko K, Benvenuto A, Hertzberg C, Benova B, Scholl T, De Ridder J, **Aronica EMA**, Kwiatkowski DJ, Jozwiak S, Jurkiewicz E, Braun K, Jansen FE; EPISTOP consortium. Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. *Neurology*. 2022 Mar 22;98(12):e1216–e1225. doi: 10.1212/WNL.0000000000200027. Epub 2022 Jan 31. PMID: 35101906 (Impact Factor 9.910) PL II
37. Johannesen KM, Iqbal S, Guazzi M, Mohammadi NA, Pérez-Palma E, Schaefer E, De Saint Martin A, Abiwarde MT, McTague A, Pons R, Piton A, Kurian MA, Ambegaonkar G, Firth H, Sanchis-Juan A, Deprez M, Jansen K, De Waele L, Briltra EH, Verbeek NE, van Kempen M, Fazeli W, Striano P, Zara F, **Visser G**, Braakman HHM, Haeusler M, Elbracht M, Vaher U, Smol T, Lemke JR, Platzer K, Kennedy J, Klein KM, Au PYB, Smyth K, Kaplan J, Thomas M, Dewenter MK, Dinopoulos A, Campbell AJ, Lal D, Lederer D, Liao VWY, Ahring PK, Møller RS, Gardella E. Structural mapping of GABRB3 variants reveals genotype–phenotype correlations. *Genet Med*. 2022 Mar;24(3):681–693. doi: 10.1016/j.gim.2021.11.004. Epub 2021 Dec 7. PMID: 34906499 (Impact Factor 8.822) PL II
38. Leitner DF, Devore S, Laze J, Friedman D, Mills JD, Liu Y, Janitz M, Anink JJ, Baayen JC, Idema S, van Vliet EA, Diehl B, Scott C, **Thijs R**, Nei M, Askenazi M, Sivathamboo S, O'Brien T, Wisniewski T, Thom M, Aronica E, Boldrini M, Devinsky O. Serotonin receptor expression in hippocampus and temporal cortex of temporal lobe epilepsy patients by postictal generalized electroencephalographic suppression duration. *Epilepsia*. 2022 Nov;63(11):2925–2936. doi: 10.1111/epi.17400. PMID: 36053862 (Impact Factor 5.864) PL II
39. Mills JD, Iyer AM, van Scheppingen J, Bongaarts A, Anink JJ, Janssen B, Zimmer TS, Spliet WG, van Rijen PC, Jansen FE, Feucht M, Hainfellner JA, Krsek P, Zamecnik J, Kotulska K, Jozwiak S, Jansen A, Lagae L, Curatolo P, Kwiatkowski DJ, Pasterkamp RJ, Senthilkumar K, von Oerthel L, Hoekman MF, Gorter JA, Crino PB, Mühlebner A, Scicluna BP, **Aronica E**. Author Correction: Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment. *Sci Rep*. 2022 Sep 14;12(1):15457. doi: 10.1038/s41598-022-20109-7. PMID: 36104396. (Impact Factor 4.379) PL II
40. Moavero R, Mühlebner A, Luinenburg MJ, Craiu D, **Aronica E**, Curatolo P. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. *Epilepsy Behav*. 2022 Jun;131(Pt B):107713. doi: 10.1016/j.yebeh.2020.107713. Epub 2021 Jan 9. PMID: 33431351 (Impact Factor 2.937) PL II
41. Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmiini A, Paglioli E, Sarnat HB, Walsh CA, Wiebe S, **Aronica E**, Baulac S, Coras R, Kobow K, Cross JH,

- Garbelli R, Holthausen H, Rössler K, Thom M, El-Osta A, Lee JH, Miyata H, Guerrini R, Piao YS, Zhou D, Blümcke I. The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission. *Epilepsia*. 2022 Aug;63(8):1899–1919. doi: 10.1111/epi.17301. Epub 2022 Jun 15. PMID: 35706131 (Impact Factor 5.864) PL II
42. Noorlag L, van Klink NEC, Kobayashi K, Gotman J, Braun KPJ, **Zijlmans M**. High-frequency oscillations in scalp EEG: A systematic review of methodological choices and clinical findings. *Clin Neurophysiol*. 2022 May;137:46–58. doi: 10.1016/j.clinph.2021.12.017. Epub 2022 Jan 20. PMID: 35272185 (Impact Factor 3.708) PL II
43. Salamone A, Terrone G, Di Sapia R, Balosso S, Ravizza T, Beltrame L, Craparotta I, Mannarino L, Cominesi SR, Rizzi M, Pauletti A, Marchini S, Porcu L, Zimmer TS, **Aronica E**, Doring M, Abrahams B, Kondo S, Nishi T, Vezzani A. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy. *Neurobiol Dis*. 2022 Oct 15;173:105835. doi: 10.1016/j.nbd.2022.105835. PMID: 35932989 (Impact Factor 5.996) PL II
44. Schwarz N, Seiffert S, Pendziwiat M, Rademacher AV, Brã Nger T, Hedrich UBS, **Augustijn PB**, Baier H, Bayat A, Bisulli F, Buono RJ, Bruria BZ, Doyle MG, Guerrini R, Heimer G, Iacomino M, Kearney H, Klein KM, Kousiappa I, Kunz WS, Lerche H, Licchetta L, Lohmann E, Minardi R, McDonald M, Montgomery S, Mulahasanovic L, Oegema R, Ortal B, Papacostas SS, Ragona F, Granata T, Reif PS, Rosenow F, Rothschild A, Scudieri P, Striano P, Tinuper P, Tanteles GA, Vetro A, Zahnert F, Goldberg EM, Zara F, Lal D, May P, Muhle H, Helbig I, Weber Y. Spectrum of Phenotypic, Genetic, and Functional Characteristics in Epilepsy Patients With KCNC2 Pathogenic Variants. *Neurology*. 2022 May 17;98(20):e2046–e2059. doi: 10.1212/WNL.0000000000200660. Epub 2022 Mar 21. PMID: 35314505 (Impact Factor 9.910) PL II
45. Shlobin NA, **Sander JW**. Current Principles in the Management of Drug-Resistant Epilepsy. *CNS Drugs*. 2022 Jun;36(6):555–568. doi: 10.1007/s40263-022-00922-4. Epub 2022 May 20. PMID: 35590042 (Impact Factor 5.749) PL II
46. Singh G, Sharma S, Bansal N, Sharma M, Chowdhury A, Sharma S, Bansal RK, Goraya JS, Setia RK, Paul BS, **Sander JW**. A cluster-randomized trial comparing home-based primary health care and usual clinic care for epilepsy in a resource-limited country. *Epilepsia Open*. 2022 Dec;7(4):781–791. doi: 10.1002/epi4.12659. Epub 2022 Oct 26. PMID: 36213959 (Impact Factor Unknown) PL II
47. Straathof EJM, Hamer EG, Hensens KJ, La Bastide-van Gemert S, **Heineman KR**, Hadders-Algra M. Development of muscle tone impairments in high-risk infants: Associations with cerebral palsy and cystic periventricular leukomalacia. *Eur J Paediatr Neurol*. 2022 Mar;37:12–18. doi: 10.1016/j.ejpn.2021.12.015. Epub 2022 Jan 1. PMID: 35007848 (Impact Factor 3.140) PL II
48. Stevelink R, Al-Toma D, Jansen FE, Lamberink HJ, Asadi-Pooya AA, Farazdaghi M, Cação G, Jayalakshmi S, Patil A, Özkara Ç, Aydın Ş, Gesche J, Beier CP, Stephen LJ, Brodie MJ, Unnithan G, Radhakrishnan A, Höfler J, Trinkka E, Krause R; EpiPGX Consortium, Irelli EC, Di Bonaventura C, Szaflarski JP, Hernández-Vanegas LE, Moya-Alfaro ML, Zhang Y, Zhou D, Pietrafusa N, Specchio N, Japaridze G, Beniczky S,

Janmohamed M, Kwan P, Syvertsen M, Selmer KK, Vorderwülbecke BJ, Holtkamp M, Viswanathan LG, Sinha S, Baykan B, Altindag E, von Podewils F, Schulz J, Seneviratne U, Vilorio-Alebesque A, Karakis I, D'Souza WJ, **Sander JW**, Koeleman BPC, Otte WM, Braun KPJ. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis. *EClinicalMedicine*. 2022 Nov 11;53:101732. doi: 10.1016/j.eclinm.2022.101732. eCollection 2022 Nov. PMID: 36467455 (Impact Factor unknown) PL II

PL III = Translational Research

49. van Andel E, **Bijlenga D**, Vogel SWN, Beekman ATF, Kooij JJS. Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep. *J Biol Rhythms*. 2022 Dec;37(6):673-689. doi: 10.1177/07487304221124659. Epub 2022 Sep 30. PMID: 36181304 (Impact Factor 3.182) PL III
50. **Bijlenga D**, Urbanus B, van der Sluiszen NNJM, Overeem S, Ramaekers JG, Vermeeren A, **Lammers GJ**. Comparing objective wakefulness and vigilance tests to on-the-road driving performance in narcolepsy and idiopathic hypersomnia. *J Sleep Res*. 2022 Jun;31(3):e13518. doi: 10.1111/jsr.13518. Epub 2021 Nov 9. PMID: 34755413 (Impact Factor 3.981) PL III
51. Ceolini E, Brunner I, **Bunschoten J**, Majoie MHJM, **Thijs RD**, Ghosh A. A model of healthy aging based on smartphone interactions reveals advanced behavioral age in neurological disease. *iScience*. 2022 Aug 5;25(8):104792. doi: 10.1016/j.isci.2022.104792. eCollection 2022 Aug 19. PMID: 36039359 (Impact Factor 5.458) PL III
52. **Demuru M**, van Blooij D, Zweiphenning W, Hermes D, Leijten F, **Zijlmans M**; RESPECT group. A Practical Workflow for Organizing Clinical Intraoperative and Long-term iEEG Data in BIDS. *Neuroinformatics*. 2022 Jul;20(3):727-736. doi: 10.1007/s12021-022-09567-6. PMID: 35244855 (Impact Factor 4.085) PL III
53. Dimakopoulos V, Gotman J, Stacey W, von Ellenrieder N, Jacobs J, Papadelis C, Cimbalnik J, Worrell G, Sperling MR, **Zijlmans M**, Imbach L, Frauscher B, Sarnthein J. Protocol for multicentre comparison of interictal high-frequency oscillations as a predictor of seizure freedom. *Brain Commun*. 2022 Jun 9;4(3):fcac151. doi: 10.1093/braincomms/fcac151. eCollection 2022. PMID: 35770134 (Impact Factor Unknown) PL III
54. Drijver AJ, Oort Q, Otten R, **Reijneveld JC**, Klein M. Is poor sleep quality associated with poor neurocognitive outcome in cancer survivors? A systematic review. *J Cancer Surviv*. 2022 May 2. doi: 10.1007/s11764-022-01213-z. Online ahead of print. PMID: 35499803 (Impact Factor 4.442) PL III
55. Douw L, Nissen IA, Fitzsimmons SMDD, Santos FAN, Hillebrand A, van Straaten ECW, Stam CJ, De Witt Hamer PC, Baayen JC, Klein M, **Reijneveld JC**, Heyer DB, Verhoog MB, Wilbers R, Hunt S, Mansvelder HD, Geurts JGG, de Kock CPJ, Goriounova NA. Cellular Substrates of Functional Network Integration and Memory in Temporal Lobe Epilepsy. *Cereb Cortex*. 2022 May 30;32(11):2424-2436. doi: 10.1093/cercor/bhab349. PMID: 34564728 (Impact Factor 5.357) PL III

56. Engelgeer A, **van Westrhenen A**, **Thijs RD**, Evers SMAA. An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utility. *Seizure*. 2022 Oct;101:156–161. doi: 10.1016/j.seizure.2022.08.003. PMID: 36030593 (Impact Factor 2.980) PL III
57. Ferreira-Atuesta C, de Tisi J, McEvoy AW, Miserocchi A, Khoury J, Yardi R, Vegh DT, Butler J, Lee HJ, Deli-Peri V, Yao Y, Wang FP, Zhang XB, Shakhathreh L, Siriratnam P, Neal A, Sen A, Tristram M, Varghese E, Biney W, Gray WP, Peralta AR, Rainha-Campos A, Gonçalves-Ferreira AJC, Pimentel J, Arias JF, Terman S, Terziev R, Lamberink HJ, Braun KPJ, Otte WM, Rugg-Gunn FJ, Gonzalez W, Bentes C, Hamandi K, O'Brien TJ, Perucca P, Yao C, Burman RJ, Jehi L, Duncan JS, **Sander JW**, Koepp M, Galovic M. Predictive models for starting antiseizure medication withdrawal following epilepsy surgery in adults. *Brain*. 2022 Nov 23:awac437. doi: 10.1093/brain/awac437. Online ahead of print. PMID: 36415957 (Impact Factor 13.501) PL III
58. Goel P, Singh G, Bansal V, Sharma S, Kumar P, Chaudhry R, Bansal N, Chaudhary A, Sharma S, **Sander JW**. Psychiatric comorbidities among people with epilepsy: A population-based assessment in disadvantaged communities. *Epilepsy Behav*. 2022 Dec;137(Pt A):108965. doi: 10.1016/j.yebeh.2022.108965. Epub 2022 Nov 4. PMID: 36343531 (Impact Factor 2.937) PL III
59. Gool JK, Zhang Z, Oei MSSL, Mathias S, Dauvilliers Y, Mayer G, Plazzi G, Del Rio-Villegas R, Cano JS, Šonka K, Partinen M, Overeem S, Peraita-Adrados R, Heinzer R, Martins da Silva A, Högl B, Wierzbicka A, Heidbreder A, Feketeova E, Manconi M, Bušková J, Canellas F, Bassetti CL, Barateau L, Pizza F, Schmidt MH, Fronczek R, Khatami R, **Lammers GJ**. Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering. *Neurology*. 2022 Jun 7;98(23):e2387–e2400. doi: 10.1212/WNL.0000000000200519. Epub 2022 Apr 18. PMID: 35437263 (Impact Factor 9.910) PL III
60. **Gool JK**, **Fronczek R**, Bosma P, van der Meer JN, van der Werf YD, **Lammers GJ**. Enhanced Visual Cortex Activation in People With Narcolepsy Type 1 During Active Sleep Resistance: An fMRI-EEG Study. *Front Neurosci*. 2022 Jun 27;16:904820. doi: 10.3389/fnins.2022.904820. eCollection 2022. PMID: 35833089 (Impact Factor 4.677) PL III
61. **van Griethuysen R**, **van Asch CJJ**, **Otte WM**, **Sander JW**, Braun KPJ. Yield and risk associated with prolonged presurgical video-EEG monitoring: a systematic review. *Epileptic Disord*. 2022 Dec 1;24(6):1–13. doi: 10.1684/epd.2022.1484. PMID: 36039766 (Impact Factor 1.819) PL III
62. Habek M, Leys F, Krbot Skorić M, Carneiro DR, Calandra-Buonaura G, Camaradou J, Chiaro G, Cortelli P, Falup-Pecurariu C, Granata R, Guaraldi P, Helbok R, Hilz MJ, Iodice V, Jordan J, Kaal ECA, Kamondi A, Pavy Le Traon A, Rocha I, Sellner J, Senard JM, Terkelsen A, Wenning GK, Berger T, **Thijs RD**, Struhal W, Fanciulli A; Collaborators of European Network of Clinical ANS laboratories. Clinical Autonomic Nervous System Laboratories in Europe. *Eur J Neurol*. 2022 Dec;29(12):3633–3646. doi: 10.1111/ene.15538. PMID: 36056590 (Impact Factor 6.089) PL III
63. Haris A, Bachour K, Hopkins RB, Tarride JE, **Keezer MR**. The treatment of epilepsy in younger and older adults: Demographic differences and prescribing patterns of anti-seizure medications in Canada. *Epilepsy Res*. 2022 Aug;184:106941. doi:

- 10.1016/j.eplepsyres.2022.106941. Epub 2022 May 13. PMID: 35785633 (Impact Factor 3.045) PL III
64. **Helling RM, Shmuelly S, Bauer PR**, Tolner EA, **Visser GH, Thijs RD**. Tracking cortical excitability dynamics with transcranial magnetic stimulation in focal epilepsy. *Ann Clin Transl Neurol*. 2022 Apr;9(4):540–551. doi: 10.1002/acn3.51535.PMID: 35297209 (Impact Factor 4.511) PL III
65. **van der Hoeven AE**, van Waaij K, **Bijlenga D**, Roelandse FWC, Overeem S, Bakker JA, **Fronczek R, Lammers GJ**. Hypocretin–1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification. *Sleep*. 2022 Jul 11;45(7):zsac103. doi: 10.1093/sleep/zsac103. PMID: 35512685 (Impact Factor 5.849) PL III
66. Hulshof HM, Kuijf HJ, Kotulska K, Curatolo P, Weschke B, Riney K, Krsek P, Feucht M, Nabbout R, Lagae L, Jansen A, Otte WM, Lequin MH, Sijko K, Benvenuto A, Hertzberg C, Benova B, Scholl T, De Ridder J, **Aronica EMA**, Kwiatkowski DJ, Jozwiak S, Jurkiewicz E, Braun K, Jansen FE; EPISTOP consortium. Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. *Neurology*. 2022 Mar 22;98(12):e1216–e1225. doi: 10.1212/WNL.0000000000200027. Epub 2022 Jan 31. PMID: 35101906 (Impact Factor 9.910) PL III
67. Khoo A, Martin L, Tisi J, O'Keefe AG, **Sander JW**, Duncan JS. Cost of pre–surgical evaluation for epilepsy surgery: A single–center experience. *Epilepsy Res*. 2022 May;182:106910. doi: 10.1016/j.eplepsyres.2022.106910. PMID: 35316729 (Impact Factor 3.045) PL III
68. Khoo A, de Tisi J, Foong J, Bindman D, O'Keefe AG, **Sander JW**, Misericocchi A, McEvoy AW, Duncan JS. Long–term seizure, psychiatric and socioeconomic outcomes after frontal lobe epilepsy surgery. *Epilepsy Res*. 2022 Oct;186:106998. doi: 10.1016/j.eplepsyres.2022.106998. PMID: 35985250 (Impact Factor 3.045) PL III
69. **Lammers GJ**. Drugs Used in Narcolepsy and Other Hypersomnias. *Sleep Med Clin*. 2022 Sep;17(3):399–405. doi: 10.1016/j.jsmc.2022.06.005. Epub 2022 Sep 1. PMID: 36150802 Review. (Impact Factor 3.492) PL III
70. Lazeron RHC, **Thijs RD**, Arends J, **Gutter T**, Cluitmans P, Van Dijk J, Tan FIY, **Hofstra W, Donjacour CEHM**, Leijten F; Dutch Tele–Epilepsy Consortium. Multimodal nocturnal seizure detection: Do we need to adapt algorithms for children? *Epilepsia Open*. 2022 Sep;7(3):406–413. doi: 10.1002/epi4.12618. Epub 2022 Jul 21. PMID: 35666848 (Impact Factor Unknown) PL III
71. Loeyts T, **Rodenburg R**. Dealing With Autocorrelation in the Single Case AB–Design: A Study Assessing the Mediating Effect of Infant Crying on the Relation Between Responsive Soothing and Infant Sleep. *Eval Health Prof*. 2022 Mar;45(1):22–35. doi: 10.1177/01632787211069678. Epub 2022 Mar 9.PMID: 35259962 (Impact Factor 2.651) PL III
72. Malhotra A, Strollo PJ Jr, Pepin JL, Schweitzer P, **Lammers GJ**, Hedner J, Redline S, Chen D, Chandler P, Bujanover S, Strohl K. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. *Sleep Med*.

2022 Dec;100:165–173. doi: 10.1016/j.sleep.2022.08.005. PMID: 36084494
(Impact Factor 3.492) PL III

73. Mooij AH, Huiskamp GJM, Aarts E, Ferrier CH, Braun KPJ, **Zijlmans M**. Accurate differentiation between physiological and pathological ripples recorded with scalp-EEG. *Clin Neurophysiol*. 2022 Nov;143:172–181. doi: 10.1016/j.clinph.2022.08.014. PMID: 36115810 (Impact Factor 3.708) PL III
74. Monahan RC, Middelkoop HA, Beart-van de Voorde LJ, **Fronczek R**, Groenwold RH, Kloppenburg M, Huizinga TW, Steup-Beekman GM. High prevalence but low impact of cognitive dysfunction on quality of life in patients with lupus and neuropsychiatric symptoms. *Arthritis Care Res (Hoboken)*. 2022 Apr 26. doi: 10.1002/acr.24904. Online ahead of print. PMID: 35470979 (Impact Factor 4.794) PL III
75. **Reus EEM, Cox FME, van Dijk JG, Visser GH**. Automated spike detection: Which software package? *Seizure*. 2022 Feb;95:33–37. doi: 10.1016/j.seizure.2021.12.012. Epub 2021 Dec 26. PMID: 34974231 (Impact Factor 2.980) PL III
76. **Reus EEM, Visser GH, van Dijk JG, Cox FME**. Automated seizure detection in an EMU setting: Are software packages ready for implementation? *Seizure*. 2022 Mar;96:13–17. doi: 10.1016/j.seizure.2022.01.009. Epub 2022 Jan 13. PMID: 35042003 (Impact Factor 2.980) PL III
77. **Sander JW**, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. *Epilepsia*. 2022 Jan;63(1):139–149. doi: 10.1111/epi.17134. Epub 2021 Nov 23. PMID: 34813673 (Impact Factor 5.864) PL III
78. Shen S, Dong Z, **Sander JW**, Zhou D, Li J. Somatic symptom and related disorder in a large cohort of people with epilepsy: a cohort study. *Epilepsia*. 2022 Nov 1. doi: 10.1111/epi.17453. Online ahead of print. PMID: 36318105 (Impact Factor 5.864) PL III
79. Straathof EJM, Hamer EG, **Heineman KR**, Hadders-Algra M. Atypical knee jerk responses in high-risk children: A longitudinal EMG-study. *Eur J Paediatr Neurol*. 2022 Sep;40:11–17. doi: 10.1016/j.ejpn.2022.07.003. Epub 2022 Jul 19. PMID: 35872514 (Impact Factor 3.140) PL III
80. Straumann S, **Schaft E**, Noordmans HJ, Dankbaar JW, Otte WM, van Steenis J, Smits P, Zweiphenning W, van Eijsden P, Gebbink T, Mariani L, Van't Klooster MA, **Zijlmans M**. The spatial relationship between the MRI lesion and intraoperative electrocorticography in focal epilepsy surgery. *Brain Commun*. 2022 Nov 21;4(6):fcac302. doi: 10.1093/braincomms/fcac302. eCollection 2022. PMID: 36519154 Free PMC article. (Impact Factor Unknown) PL III
81. Vinckenbosch F, Asin J, de Vries N, Vonk PE, **Donjacour CEHM, Lammers GJ**, Overeem S, Janssen H, Wang G, Chen D, Carter LP, Zhou K, Vermeeren A, Ramaekers JG. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. *Hum Psychopharmacol*. 2022 Nov;37(6):e2845. doi: 10.1002/hup.2845. PMID: 35633275 (Impact Factor 1.672) PL III
82. Vinckenbosch F, **Lammers GJ**, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. *Hum Psychopharmacol*.

2023 Jan;38(1):e2858. doi: 10.1002/hup.2858. Epub 2022 Nov 24. PMID: 36420633. (Impact Factor 2.112) PL III

83. **van Westrhenen A**, Wijnen BFM, **Thijs RD**. Parental preferences for seizure detection devices: A discrete choice experiment. *Epilepsia*. 2022 May;63(5):1152–1163. doi: 10.1111/epi.17202.PMID: 35184284 (Impact Factor 5.864) PL III
84. Wjibenga RA, Blaauw FJ, Janus SIM, Tibben C, **Smits AE**, Oude Voshaar RC, Zuidema SU, Zuidersma M. Individual differences in the temporal relationship between sleep and agitation: a single–subject study in nursing home residents with dementia experiencing sleep disturbance and agitation. *Aging Ment Health*. 2022 Aug;26(8):1669–1677. doi: 10.1080/13607863.2021.1935464. Epub 2021 Jun 15. PMID: 34129803 (Impact Factor 3.658) PL III
85. Zhang Z, Dauvilliers Y, Plazzi G, Mayer G, **Lammers GJ**, Santamaria J, Partinen M, Overeem S, Del Rio Villegas R, Sonka K, Peraita–Adrados R, Heinzer R, Wierzbicka A, Högl B, Manconi M, Feketeova E, da Silva AM, Bušková J, Bassetti CLA, Barateau L, Pizza F, Antelmi E, **Gool JK**, **Fronczek R**, Gaig C, Khatami R. Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. *Nat Sci Sleep*. 2022 May 31;14:1031–1047. doi: 10.2147/NSS.S359980. eCollection 2022. PMID: 35669411 (Impact Factor 5.346) PL III

PL IV = Sleep

86. Kallweit U, Pevernagie D, **Lammers GJ**. "Sleepiness" in obstructive sleep apnea: getting into deep water. *Sleep Med*. 2022 Apr;92:64–66. doi: 10.1016/j.sleep.2022.02.015. Epub 2022 Feb 25. PMID: 35339741 (Impact Factor 3.492) PL IV
87. Lammers–van der Holst HM, **Lammers GJ**, van der Horst GTJ, Chaves I, de Vries RD, GeurtsvanKessel CH, Koch B, van der Kuy HM. Understanding the association between sleep, shift work and COVID–19 vaccine immune response efficacy: Protocol of the S–CORE study. *J Sleep Res*. 2022 Apr;31(2):e13496. doi: 10.1111/jsr.13496. Epub 2021 Oct 6.PMID: 34617358 (Impact Factor 3.981) PL IV
88. Shan L, Balesar R, Swaab DF, **Lammers GJ**, **Fronczek R**. Reduced Numbers of Corticotropin–Releasing Hormone Neurons in Narcolepsy Type 1. *Ann Neurol*. 2022 Feb;91(2):282–288. doi: 10.1002/ana.26300. Epub 2022 Jan 19.PMID: 34981555 (Impact Factor 10.422) PL IV